Behcet’s Disease and Your Retina: A Patient Guide
Understanding Behcet's Disease
Behcet's disease is a chronic autoimmune inflammatory disorder. In autoimmune conditions, the body's immune system mistakenly attacks its own healthy tissues. Behcet's disease causes inflammation in blood vessels throughout the body, a condition known as vasculitis.
The hallmark signs of Behcet's disease include painful mouth sores (oral aphthous ulcers), genital ulcers, skin lesions, and eye inflammation. Because the disease can affect blood vessels of all sizes in many organ systems, it is classified as a multisystemic disorder. The disease follows a pattern of flare-ups and quiet periods, with inflammation returning in repeated episodes over time.
Ocular involvement occurs in nearly 50% of patients with Behcet's disease, though the eyes are the first sign of the condition in fewer than 20% of cases (IntechOpen, 2017). When the disease does involve the eyes, it can cause several types of inflammation inside the eye, collectively known as uveitis (inflammation of the middle layer of the eye wall).
The most common form of eye involvement is panuveitis, meaning inflammation that affects both the front and back portions of the eye. Behcet's disease causes a specific type called nongranulomatous panuveitis. Inside the eye, white blood cells called leukocytes infiltrate blood vessels, leading to retinal vasculitis (inflammation of the blood vessels in the retina). This inflammation can cause blood vessel blockages, blood clots, and swelling in the macula (the central part of the retina responsible for sharp vision).
Uveitis can be an initial symptom in 10 to 20% of Behcet's disease cases and leads to blindness in 16 to 25% of affected patients (PMC, 2021). Each episode of inflammation can cause cumulative damage to delicate retinal tissue. Without prompt treatment, repeated flare-ups may result in irreversible vision loss. Early and effective treatment is critical to preventing permanent eye damage.
Who Is Affected and Risk Factors
Behcet's disease is relatively rare in Western countries, with an overall incidence of approximately 0.38 per 100,000 people and a prevalence of about 5.2 per 100,000 (PMC, 2011). However, the disease is far more common along the ancient Silk Road trade route, which stretches from eastern Asia through the Middle East to the Mediterranean. In Japan, Behcet's disease is a leading cause of blindness.
The strongest known genetic risk factor for Behcet's disease is a gene called HLA-B51, also referred to as HLA-B5. People who carry this gene have a higher chance of developing the condition compared to those who do not. HLA-B51 is more common in Turkish, Middle Eastern, and Japanese populations, which corresponds with the higher rates of Behcet's disease seen in these groups.
Behcet's disease typically develops in adults between the ages of 20 and 40. Males are more likely to develop severe forms of the disease, including eye involvement, blood vessel clots (thrombophlebitis), lung problems, and neurological complications.
Several factors increase the risk of poor vision outcomes in Behcet's disease:
- Younger age when the disease first appears
- Male gender
- Presence of skin lesions or joint inflammation (arthritis)
- Neurological involvement
- Blood vessel clots (vascular thromboses)
- More than three episodes of posterior uveitis per year
- Dense clouding of the vitreous (the gel inside the eye)
- Presence of inflammatory deposits on the retina (retinal infiltrates)
Signs and Symptoms
Anterior uveitis affects the front part of the eye and tends to cause more noticeable symptoms. When the front of the eye is inflamed, patients may experience eye pain, redness of the white part of the eye (conjunctival redness), sensitivity to light (photophobia), excessive tearing, blurry vision, and decreased sharpness of vision.
A classic but dramatic finding in Behcet's disease is called hypopyon, which is a visible layer of white blood cells that settles at the bottom of the front chamber of the eye. This sterile (non-infectious) hypopyon was one of the original signs described by the doctor who identified the disease. However, it occurs in only about one-third of cases.
Posterior uveitis affects the back of the eye, including the retina and the vitreous. This form can be more dangerous because it often causes fewer obvious symptoms while quietly damaging the retina. Patients may notice a painless decrease in vision, new floaters (spots or cobwebs drifting in the field of vision), or blank spots in their side vision (visual field defects).
During an eye examination, a retina specialist will look for specific indicators of active Behcet's disease. These include cells and protein (called flare) floating in the front chamber of the eye, haziness in the vitreous gel, and whitish coating or leakage around retinal blood vessels (vascular sheathing). A distinctive finding is the appearance of small pearl-like deposits on the surface of the retina, which may later disappear. The specialist also checks for vitritis (inflammation in the vitreous), retinitis (inflammation of the retinal tissue), papillitis (swelling of the optic nerve head), and macular edema (swelling in the center of the retina).
Diagnosis and Testing
There is no single blood test that confirms Behcet's disease. Diagnosis is based on a combination of clinical findings. A retina specialist and other physicians work together to identify the pattern of symptoms. Recurrent oral ulcers are typically required for diagnosis, along with at least two of the following: genital ulcers, eye inflammation (uveitis), skin lesions, or a positive pathergy test (an exaggerated skin reaction to a minor needle prick).
Genetic testing for HLA-B51 may be performed to support the diagnosis, although having the gene alone does not confirm the disease. Blood tests may also be ordered to rule out other conditions that mimic Behcet's disease.
A thorough dilated eye examination is the cornerstone of evaluating ocular Behcet's disease. The retina specialist uses a slit lamp (a specialized microscope) to examine the front and back of the eye. Optical coherence tomography, or OCT (a scan that creates detailed cross-sectional images of the retina), helps detect macular edema and retinal damage.
Fluorescein angiography is another important test. A special dye is injected into a vein in the arm, and photographs of the retina are taken as the dye flows through the retinal blood vessels. This test reveals areas of blood vessel leakage, blockage, and active vasculitis. These imaging studies help the retina specialist assess how much damage has occurred and guide treatment decisions.
Because Behcet's disease affects many organ systems, patients often see a team of specialists. A rheumatologist (a doctor specializing in autoimmune and inflammatory conditions) typically coordinates overall disease management. A retina specialist manages the eye-related complications. Depending on other symptoms, a dermatologist, neurologist, or vascular specialist may also be involved in care.
Treatment Options
Corticosteroids are the primary first-response treatment for active eye inflammation in Behcet's disease. For anterior uveitis limited to the front of the eye, topical steroid eye drops may be sufficient. For more severe inflammation affecting the back of the eye, such as posterior uveitis or panuveitis, systemic corticosteroids (taken by mouth or given by injection) are often necessary to quickly reduce inflammation.
While corticosteroids are highly effective at controlling acute flare-ups, they carry significant side effects with long-term use, including elevated eye pressure (which can lead to glaucoma), cataracts, weight gain, bone thinning, and elevated blood sugar. For this reason, corticosteroids are typically used for short-term control while longer-acting treatments are started.
Because Behcet's disease is a chronic condition with recurring flare-ups, long-term immunosuppressive therapy is usually needed. Azathioprine is considered the first-line immunosuppressive agent for Behcet's disease with eye involvement. It works by dampening the overactive immune response that causes inflammation.
Other commonly used conventional immunosuppressants include:
- Cyclosporine, which suppresses specific immune cells involved in the inflammatory process
- Methotrexate, which reduces immune system activity and inflammation
These medications are typically used in combination with or as a replacement for systemic corticosteroids to maintain long-term disease control while reducing steroid-related side effects.
The introduction of biologic therapies, particularly anti-tumor necrosis factor (anti-TNF) agents, has significantly improved outcomes for patients with Behcet's disease affecting the eyes. These medications target specific proteins involved in the inflammatory process. Two key anti-TNF agents used in ocular Behcet's disease are infliximab and adalimumab.
A large multicenter study comparing infliximab and adalimumab as first-line treatment in 177 patients with refractory uveitis due to Behcet's disease found that both drugs improved outcomes after one year. However, patients receiving adalimumab showed significantly better results in several measures, including improvement in anterior chamber inflammation (92.31% vs. 78.18% for infliximab), improvement in vitritis (93.33% vs. 78.95% for infliximab), and better visual acuity outcomes (PMC, 2021). Interferon-alpha is another biologic option with confirmed efficacy and safety for ocular Behcet's disease.
Apremilast (Otezla) is an oral selective phosphodiesterase 4 (PDE4) inhibitor. It is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) specifically for oral ulcers associated with Behcet's disease, prescribed as a 30 mg twice-daily tablet for adults. While it is primarily approved for oral ulcers, its role in managing the broader disease is being studied.
Promising results are also emerging with other biologic agents for cases that do not respond to standard therapy. These include interleukin-1 (IL-1) inhibitors, ustekinumab, secukinumab, and tocilizumab. Research into these medications continues, and they may offer additional options for patients with difficult-to-control disease.
What to Expect
Behcet's disease is a chronic condition characterized by periods of active inflammation (flare-ups) alternating with periods of remission (quiet phases). The frequency and severity of flare-ups vary from person to person. Some patients experience occasional mild episodes, while others have frequent severe attacks that threaten vision.
Each inflammatory episode carries the risk of cumulative retinal damage. The goal of treatment is to reduce the frequency and severity of flare-ups to preserve as much vision as possible over the long term. With modern immunosuppressive and biologic therapies, many patients achieve better disease control than was possible in previous decades.
Immunosuppressive medications may take several weeks to reach full effectiveness. During this time, corticosteroids often serve as a bridge to control active inflammation. Patients typically need regular follow-up appointments with their retina specialist, often every few weeks during active disease and every few months during stable periods.
Monitoring visits typically include a dilated eye exam, OCT imaging, and sometimes fluorescein angiography. Blood tests may also be needed periodically to monitor for side effects of immunosuppressive medications. Consistent follow-up is critical because inflammation can return without obvious symptoms, particularly in posterior uveitis.
Visual outcomes in Behcet's disease depend on several factors, including how early treatment begins, how well inflammation is controlled, and how many flare-ups occur. With aggressive modern therapy, many patients maintain functional vision. However, some patients do experience significant vision loss, particularly if the disease is diagnosed late, treatment is delayed, or the condition proves resistant to therapy. The introduction of biologic agents has significantly reduced the rate of severe visual complications compared to earlier treatment approaches.
Living With Behcet's Disease
Living with Behcet's disease requires a commitment to ongoing medical care and medication adherence. Skipping doses of immunosuppressive medications can increase the risk of inflammatory flare-ups and cumulative retinal damage. Patients should communicate openly with their retina specialist and rheumatologist about any side effects or concerns with their medications so that adjustments can be made.
Keeping a symptom diary can help patients track patterns in their disease, including potential triggers for flare-ups. Stress management, adequate sleep, and a balanced diet may support overall health, though no specific lifestyle changes have been proven to prevent Behcet's flare-ups.
Patients with ocular Behcet's disease should be vigilant about changes in their vision. Wearing sunglasses outdoors can help manage light sensitivity. Using prescribed eye drops exactly as directed is important during and after flare-ups. Patients should not adjust or stop any medications without consulting their retina specialist or prescribing physician.
It is also helpful to maintain relationships with all members of the care team, including the rheumatologist who manages the systemic aspects of the disease and the retina specialist who monitors eye health.
Living with a rare chronic disease can be emotionally challenging. Anxiety about potential vision loss, the burden of frequent medical appointments, and the side effects of medications can all take a toll. Support groups for patients with Behcet's disease, both in person and online, can provide valuable connections with others who understand the experience. Counseling or therapy may also help patients cope with the psychological impact of chronic illness.
When to See a Retina Specialist
Certain symptoms require immediate attention. If you have been diagnosed with Behcet's disease, or if you have a history of uveitis, see a retina specialist or go to the emergency room immediately if you experience any of the following:
- Sudden decrease in vision in one or both eyes
- A sudden increase in floaters
- Flashes of light in your vision
- A shadow or curtain appearing over part of your visual field
- New or worsening eye pain with redness
These symptoms may indicate a severe inflammatory flare-up, retinal vasculitis, or a retinal complication that requires urgent treatment.
Even during periods when the eyes feel comfortable and vision seems stable, regular monitoring with a retina specialist is important. Posterior uveitis and retinal vasculitis can progress without causing obvious symptoms. Routine examinations allow the retina specialist to detect early signs of recurrent inflammation and adjust treatment before significant damage occurs. The frequency of these visits depends on disease activity and treatment status, but most patients require examinations at least every few months.
Questions and Answers
Behcet's disease is a chronic condition that is managed, not cured. The goal of treatment is to control inflammation, reduce the frequency and severity of flare-ups, and prevent complications such as vision loss. With consistent medical care and modern therapies, many patients achieve long periods of remission where the disease is well controlled.
Not all patients with ocular Behcet's disease lose significant vision. The risk of vision loss depends on several factors, including how quickly treatment begins, how well the inflammation responds to therapy, and how often flare-ups occur. Modern biologic therapies have improved visual outcomes substantially. However, delayed treatment or frequent severe flare-ups increase the risk of permanent damage. Consistent follow-up with a retina specialist gives you the best chance of preserving your sight.
Most patients with ocular Behcet's disease require immunosuppressive therapy for many years, and some may need it indefinitely. Your retina specialist and rheumatologist will periodically evaluate whether it is safe to reduce or adjust your medications based on how well the disease is controlled. Stopping medication too early or without medical guidance can trigger a damaging flare-up.
Behcet's disease is not contagious. You cannot catch it from another person or spread it to others. While certain genes like HLA-B51 increase the risk of developing the disease, Behcet's is not directly inherited in a simple pattern. Having a family member with Behcet's disease may slightly increase your risk, but most people who carry the associated genes do not develop the condition.
Anterior uveitis involves inflammation in the front part of the eye and typically causes noticeable symptoms like pain, redness, and light sensitivity. Posterior uveitis involves inflammation in the back of the eye, including the retina and vitreous. Posterior uveitis is often more dangerous because it can damage the retina with fewer obvious symptoms. Many patients with ocular Behcet's disease develop panuveitis, which affects both the front and back of the eye simultaneously. Regular examinations with a retina specialist are important because posterior inflammation may not cause pain or redness.